Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.55
-0.0800-3.04%
Post-market: 2.610.0600+2.35%19:53 EDT
Volume:110.24K
Turnover:281.00K
Market Cap:85.11M
PE:-8.09
High:2.83
Open:2.63
Low:2.50
Close:2.63
52wk High:5.46
52wk Low:2.33
Shares:33.38M
Float Shares:30.46M
Volume Ratio:0.87
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3151
EPS(LYR):-0.3367
ROE:-68.07%
ROA:-40.39%
PB:5.65
PE(LYR):-7.57

Loading ...

Anixa Biosciences Receives Notice of Allowance From Mexican Institute of Industrial Property (Impi) for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Jan 27

Anixa Biosciences posts FY2025 interest income of USD 0.7 million, down 41 percent

Reuters
·
Jan 13

Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters
·
Dec 15, 2025

Anixa Biosciences Announces Transfer of Ind for Breast Cancer Vaccine From Cleveland Clinic

THOMSON REUTERS
·
Dec 15, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM

Reuters
·
Dec 12, 2025

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 12, 2025

Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Reuters
·
Dec 12, 2025

Anixa Biosciences Inc - Vaccine Safe and Well Tolerated at Maximum Dose

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Dec 10, 2025

Anixa Biosciences Secures WHO Approval for CAR-T Therapy Name

Reuters
·
Nov 17, 2025

Anixa Biosciences Announces World Health Organization (Who) Approval of International Non-Proprietary Name for Its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

THOMSON REUTERS
·
Nov 17, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)

TIPRANKS
·
Nov 07, 2025

BRIEF-Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Reuters
·
Nov 05, 2025

Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters
·
Nov 05, 2025

Anixa Biosciences to Present at Spartan Capital Securities Second Annual Investor Conference

Reuters
·
Oct 23, 2025

Anixa Biosciences Secures Chinese Patent for Breast Cancer Vaccine Technology

Reuters
·
Oct 20, 2025

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Oct 20, 2025

Anixa Biosciences Completes Phase 1 Breast Cancer Vaccine Trial and Plans Results Presentation in 2025

Reuters
·
Oct 08, 2025